Amplia Therapeutics (ASX:ATX) has provided an update on the ongoing ACCENT trial investigating its FAK inhibitor narmafotinib in advanced pancreatic cancer. …
Amplia announces second confirmed complete response in ACCENT trial
June 19, 2025 Australian Biotech
Latest Video
New Stories
-
'No data means no prospect of access to trials or funded medicines'
July 30, 2025 - - Latest News -
The problem with the minister's statement is that it's entirely accurate
July 30, 2025 - - Latest News -
Plenty going on behind the scenes, but the industry so far is mostly favouring public silence
July 30, 2025 - - Latest News -
World-first study uses DNA to investigate who develops MS and why
July 30, 2025 - - Latest News -
Government moves on general co-pay as safety net gets further out of reach
July 29, 2025 - - Latest News -
'For these families, genomics is not a luxury—it’s the only viable path'
July 29, 2025 - - Latest News -
Pharmac identifies the wider societal benefit of treatments for chronic conditions
July 28, 2025 - - Latest News